1. Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results
- Author
-
Alfonso Zaccaria, Francesco Passamonti, Simona Bulgarelli, E. De Biasi, Vincenzo Martinelli, Emma Cacciola, Antonio Tabilio, Anna Candoni, Alessia Tieghi, Alberto Grossi, P. Favini, Roberto Latagliata, Silvia Asioli, Stefano Sacchi, Michele Baccarani, Maurizio Miglino, Luigi Gugliotta, Nicola Vianelli, Serena Rupoli, G. Gardini, Francesco Lauria, G. Pisapia, Gugliotta, L., Bulgarelli, S., Tieghi, A., Asioli, S., Gardini, G., Vianelli, N., Candoni, A., Latagliata, R., Rupoli, S., Martinelli, Vincenzo, Zaccaria, A., DE BIASI, E., Sacchi, S., Lauria, F., Miglino, M., Passamonti, F., Tabilio, A., Cacciola, E., Grossi, A., Pisapia, G., Favini, P., and Baccarani, M.
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Essential thrombocythemia ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Granulopoiesis ,Surgery ,medicine.anatomical_structure ,Tolerability ,Fibrosis ,Internal medicine ,PEG ratio ,Biopsy ,medicine ,Platelet ,nd ,Bone marrow ,business - Abstract
Ninety patients with Essential Thrombocythemia (ET) where object of a phase II prospective multicentre study designed to evaluate efficacy, safety and tolerability of a two years treatment with PEG Interferon α-2b (PEG Intron, Schering Plough). The patients, 30 M and 60 F, 18–72 years old (median 45), observed in 16 Hematological Institutions of the Gruppo Italiano Malattie Mieloproliferative Croniche (GIMMC), received the ET diagnosis according to the PVSG criteria. At PEG Intron treatment start the patients showed: previous cytoreduction 97% (IFN α 31%), platelet count >1000 x 109/L 81%, splenomegaly 22%. At the end of the first year The PEG Intron starting dose of 25 μg/week resulted increased to a mean value of 55 μg/week and the Hematological Response (HR = Plts 45 years, platelet count >1000 x109/L, Hb 50 μg/week. In conclusion, the present study shows that in ET patients a two years PEG Intron treatment, able to induce and to maintain the Hematological Response in the majority of cases, is associated to a decrease of bone marrow cellularity, granulopoiesis, erytropoiesis, MK number, size and ploidy and, moreover, with an increase of MK dystrophy and of bone marrow fibrosis. These preliminary data on bone biopsy and aspirate will be object of a planned centralized reevaluation by a Panel of Pathologists and Clinicians.
- Published
- 2004
- Full Text
- View/download PDF